CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

SAN DIEGO–(BUSINESS WIRE)– #TCT2019–FIH data shows that RUC-4, a novel subcutaneous platelet GPIIb/IIIa inhibitor, resulted in a potent, rapid, and sustained platelet inhibition effect.